诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVO 诺和诺德

休市中 11-22 16:00:00 EST

105.06

+2.43

+2.37%

盘后105.09

+0.03+0.03%

19:58 EST

最高106.24	最低103.86	成交量614.33万
今开103.91	昨收102.63	日振幅2.32%
总市值4,668亿	流通市值3,341亿	总股本44.43亿
成交额6.46亿	换手率0.19%	流通股本31.80亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":105.06,"timestamp":1732309200000,"preClose":102.63,"halted":0,"volume":6143255,"hourTrading":{"tag":"盘后","latestPrice":105.09,"preClose":105.06,"latestTime":"19:58 EST","volume":882195,"amount":92805887.9725,"timestamp":1732323520336},"delay":0,"floatShares":3179806643,"shares":4443220356,"eps":3.170878,"marketStatus":"休市中","marketStatusCode":7,"change":2.43,"latestTime":"11-22 16:00:00 EST","open":103.91,"high":106.24,"low":103.86,"amount":645622189.7324001,"amplitude":0.02319,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.170878,"exchange":"NYSE","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1732525200000},"adr":1,"listingDate":363499200000,"adjPreClose":102.63,"adrRate":1,"dividendRate":0.013868,"preHourTrading":{"tag":"盘前","latestPrice":103.88,"preClose":102.63,"latestTime":"09:29 EST","volume":85409,"amount":8812571.50947,"timestamp":1732285796237},"postHourTrading":{"tag":"盘后","latestPrice":105.09,"preClose":105.06,"latestTime":"19:58 EST","volume":882195,"amount":92805887.9725,"timestamp":1732323520336},"volumeRatio":0.8946200892333009,"optionData":{"bulkOrders":[{"symbol":"NVO","call":true,"expireDate":1737090000000,"strike":"115.0","timestamp":1732289236953,"price":3.8399999141693115,"volume":1801,"amount":691584,"type":"+"},{"symbol":"NVO","call":true,"expireDate":1734670800000,"strike":"102.0","timestamp":1732289653912,"price":7.800000190734863,"volume":1750,"amount":1365000,"type":"+"}]},"impliedVol":0.5349,"impliedVolPercentile":0.9722},"requestUrl":"/m/hq/s/NVO","defaultTab":"news","newsList":[{"id":"2485722009","title":"欧盟或将无条件批准诺和诺德(NVO.US)母公司收购Catalent(CTLT.US)","url":"https://stock-news.laohu8.com/highlight/detail?id=2485722009","media":"智通财经","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485722009?lang=zh_cn&edition=full","pubTime":"2024-11-23 14:50","pubTimestamp":1732344657,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据报道，欧盟委员会可能将无条件批准诺和诺德 母公司Novo Holdings以165亿美元收购美国合同制药商Catalent的交易。今年2月，Catalent同意以每股63.50美元的价格被Novo Holdings收购。Novo Holdings随后将向诺和诺德出售三个Catalent生产基地，这将有助于诺和诺德提高其畅销减肥药Wegovy的产量。诺和诺德和Catalent最近都重申了它们的预期，即交易将在今年年底前完成。截至周五收盘，Catalent涨2.21%，报60.98美元；诺和诺德涨2.37%，报105.06美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0154236417.USD","BK4585","BK4532","BK4007","BK4588","NVO","IE00BKVL7J92.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","CTLT","LU1093756168.USD","BK4530","BK4599"],"gpt_icon":1},{"id":"2485326825","title":"诺和诺德(NVO.US)与Ypsomed签订合同生产下一代减肥药注射笔","url":"https://stock-news.laohu8.com/highlight/detail?id=2485326825","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485326825?lang=zh_cn&edition=full","pubTime":"2024-11-22 21:30","pubTimestamp":1732282249,"startTime":"0","endTime":"0","summary":"智通财经获悉，知情人士透露，诺和诺德与瑞士医疗器械制造商Ypsomed 签订合同，Ypsomed 将为诺和诺德的下一代肥胖治疗药物CagriSema提供注射笔。semaglutide是诺和诺德流行的减肥疗法Wegovy的活性成分。诺和诺德希望在一年内实现25%的平均减肥效果，相比之下，其竞争对手礼来开发的减肥疗法Zepbound在一年内分别实现了15%和20%的平均减肥效果。去年，Ypsomed 签署了一项长期协议，为诺和诺德提供旨在为多种代谢疾病提供自我给药治疗的自动注射器。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214940.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4007","BK4585","LU1093756325.SGD","LU1093756168.USD","NVO","BK4532","IE00BKVL7J92.USD","BK4599","IE00BZ1G4Q59.USD","LU0154236417.USD"],"gpt_icon":0},{"id":"2485427606","title":"网红减肥药正式上市单支超千元 电商平台预约量持续走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2485427606","media":"金羊网","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485427606?lang=zh_cn&edition=full","pubTime":"2024-11-22 07:10","pubTimestamp":1732230636,"startTime":"0","endTime":"0","summary":"马斯克带火的网红减肥药这回正式上市了。11月17日，诺和诺德宣布其用于长期体重管理的胰高糖素样肽-1受体激动剂（GLP-1RA）周制剂司美格鲁肽（商品名：诺和盈）正式在中国上市，为中国超重和肥胖症患者提供减重选择。当前，包括上海、广州多地的公立医院也陆续开出诺和盈的首方。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411223247104823.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411223247104823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","LU1093756325.SGD","BK4599","LU0154236417.USD","NVO","BK4532","BK4007","BK4588","LU1093756168.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2485559534","title":"诺和盈减重药京东销售火爆 价格最高达1700元每支","url":"https://stock-news.laohu8.com/highlight/detail?id=2485559534","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485559534?lang=zh_cn&edition=full","pubTime":"2024-11-21 16:15","pubTimestamp":1732176925,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4505","LU0384037296.USD","LU0791590937.USD","BK1610","BK4579","LU0543330483.HKD","LU1282649810.SGD","IE00BGV7N243.SGD","BK4503","BK4504","LU0315178854.USD","LU0868486357.SGD","LU0348805143.USD","BK1142","BK4590","LU0051755006.USD","LU0572944931.SGD","09618","LU0370786039.SGD","LU0588545730.USD","LU0048580855.USD","LU0348825331.USD","LU0456827905.SGD","LU0320764755.SGD","LU0865486749.SGD","NVO","89618","LU1044875133.USD","LU2242644610.SGD","BK1575","SG9999002562.SGD","BK4588","LU0588546209.SGD","GLP","JD","LU0327786744.USD","LU0417516738.SGD","LU0588545904.SGD","LU1366334578.USD","LU1093756168.USD","IE00BZ1G4Q59.USD","LU0228367735.SGD","LU0315179316.USD","LU1023057109.AUD","BK4532","IE00BKVL7J92.USD","LU0463099449.HKD","LU0588545490.SGD","BK4526","LU0052750758.USD"],"gpt_icon":0},{"id":"1106223865","title":"政策压力下率先反弹，“减肥药新贵”Viking能否抗衡“诺礼双雄”？","url":"https://stock-news.laohu8.com/highlight/detail?id=1106223865","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106223865?lang=zh_cn&edition=full","pubTime":"2024-11-20 18:33","pubTimestamp":1732098801,"startTime":"0","endTime":"0","summary":"不过从实际情况来看，肥胖人群对减肥药物的需求持续高企，而“减肥药新贵” Viking的新型口服减肥药VK2809后来居上，甚至有力压老牌减肥药物巨头“诺礼双雄”的势头。此前，Viking还公布了VK2735注射版的最新数据。考虑到规模及品牌效应，目前主导肥胖药物领域的仍然是诺和诺德和礼来两大巨头，但“减肥药新贵”Viking的异军突起，或许将让他们未来面临严峻的竞争。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","VKTX","LLY"],"gpt_icon":0},{"id":"2484539138","title":"减重版司美格鲁肽国内开卖，预约价格上涨，产能限制或为同业留出追赶窗口期丨钛媒体焦点","url":"https://stock-news.laohu8.com/highlight/detail?id=2484539138","media":"钛媒体","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484539138?lang=zh_cn&edition=full","pubTime":"2024-11-20 10:06","pubTimestamp":1732068366,"startTime":"0","endTime":"0","summary":"11月18日，减重版司美格鲁肽在上海复旦大学附属医院开出全国首批处方。对于减重版司美格鲁肽诺和盈，国家医保局官方曾明确发文称，不会纳入医保。这既增加了诺和诺德占据中国市场的紧迫性，也为仿制药企留出了追赶窗口期。图源自华福证券研报此前，高盛分析师在报告中指出，仿制药的进入可能导致司美格鲁肽在中国的价格大幅下降，幅度或高达四分之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120100938a2473b22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120100938a2473b22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","LU1093756325.SGD","IE00BKVL7J92.USD","BK4532","NVO","BK4588","BK4585","LU0154236417.USD","BK4007","LU1093756168.USD"],"gpt_icon":0},{"id":"2484280259","title":"诺和诺德涨1.57% 股价突破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2484280259","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484280259?lang=zh_cn&edition=full","pubTime":"2024-11-19 22:31","pubTimestamp":1732026683,"startTime":"0","endTime":"0","summary":"北京时间2024年11月19日22时31分，诺和诺德股票出现异动，股价急速上涨1.57%。截至发稿，该股报101.38美元/股，成交量32.1208万股，换手率0.01%，振幅0.24%。诺和诺德股票所在的制药行业中，整体跌幅为0.62%。诺和诺德公司简介：诺和诺德拥有全球约三分之一的品牌糖尿病治疗市场，是全球领先的糖尿病护理产品供应商。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111922312395be4a83&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111922312395be4a83&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVO","IE00BKVL7J92.USD","BK4585","LU1093756168.USD","LU0154236417.USD","IE00BZ1G4Q59.USD","BK4532","BK4588","BK4007","LU1093756325.SGD"],"gpt_icon":1},{"id":"2484917752","title":"诺和诺德减重版司美格鲁肽获批 GLP-1市场依然“热辣滚烫”","url":"https://stock-news.laohu8.com/highlight/detail?id=2484917752","media":"国际金融报","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484917752?lang=zh_cn&edition=full","pubTime":"2024-11-19 19:25","pubTimestamp":1732015526,"startTime":"0","endTime":"0","summary":"近日，丹麦生物制药公司诺和诺德宣布，全球首个且目前唯一用于长期体重管理的胰高糖素样肽-1受体激动剂（GLP-1RA）周制剂诺和盈正式在中国上市。据了解，诺和盈（用于长期体重管理的司美格鲁肽注射液）能够实现平均约17%的体重降幅。此前，诺和诺德生产的司美格鲁肽注射剂降糖适应证已于2021年在国内获批。从市场格局来看，目前国内已有多款GLP-1类减肥药获批。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411193244417043.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411193244417043.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4588","BK4007","GLP","BK4585","IE00BKVL7J92.USD","LU0154236417.USD","BK4144","NVO","LU1093756168.USD","BK4590","LU1093756325.SGD","BK4532","IE00BZ1G4Q59.USD"],"gpt_icon":1},{"id":"2484916013","title":"诺和诺德欧股下跌1.2%，抹去年初至今的涨幅。","url":"https://stock-news.laohu8.com/highlight/detail?id=2484916013","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484916013?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:36","pubTimestamp":1732012609,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4585","LU1093756325.SGD","LU0154236417.USD","NVO","BK4532","BK4007","BK4588","LU1093756168.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"1157085367","title":"诺和诺德在中国市场收获利好，减重版司美格鲁肽已商业化上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1157085367","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157085367?lang=zh_cn&edition=full","pubTime":"2024-11-19 13:24","pubTimestamp":1731993849,"startTime":"0","endTime":"0","summary":"价格相比于美国市场销售价格的便宜得多。","market":"us","thumbnail":"https://static.tigerbbs.com/045e965ac1c01cc7a265a286f32bc8dd","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/045e965ac1c01cc7a265a286f32bc8dd"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1212716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NVO"],"gpt_icon":0},{"id":"2484294676","title":"诺和诺德跌1.78% 股价跌破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2484294676","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484294676?lang=zh_cn&edition=full","pubTime":"2024-11-18 22:47","pubTimestamp":1731941260,"startTime":"0","endTime":"0","summary":"北京时间2024年11月18日22时47分，诺和诺德股票出现异动，股价大幅跳水1.78%。截至发稿，该股报99.93美元/股，成交量49.2902万股，换手率0.01%，振幅0.53%。诺和诺德股票所在的制药行业中，整体跌幅为1.51%。诺和诺德公司简介：诺和诺德拥有全球约三分之一的品牌糖尿病治疗市场，是全球领先的糖尿病护理产品供应商。诺和诺德还有一个生物制药部门，专门从事血友病和其他疾病的蛋白质疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118224741abccb504&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118224741abccb504&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ1G4Q59.USD","BK4007","IE00BKVL7J92.USD","LU1093756168.USD","LU1093756325.SGD","BK4585","NVO","BK4532","LU0154236417.USD","BK4588"],"gpt_icon":1},{"id":"2484246776","title":"“减肥神药”官宣上市，多款国产药有望获批 减肥药江湖谁主沉浮？","url":"https://stock-news.laohu8.com/highlight/detail?id=2484246776","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484246776?lang=zh_cn&edition=full","pubTime":"2024-11-18 20:38","pubTimestamp":1731933536,"startTime":"0","endTime":"0","summary":"11月17日，生物制药公司诺和诺德宣布，全球首个且目前唯一用于长期体重管理的GLP-1RA（胰高糖素样肽-1受体激动剂）周制剂诺和盈（用于长期体重管理的司美格鲁肽注射液）正式在中国上市。据悉，诺和盈能实现平均约17%的体重降幅，其减重效果至少可以持续两年。一项临床研究结果显示，诺和盈带来的体重减轻以脂肪组织的减少为主。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411183243138286.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411183243138286.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1093756168.USD","LU1093756325.SGD","IE00BKVL7J92.USD","LU0154236417.USD","BK4585","BK4157","BK4588","IE00BZ1G4Q59.USD","BMI","BK4007","NVO","BK4532"],"gpt_icon":1},{"id":"2484625898","title":"巴克莱分析师：2025年制药行业前景更具挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2484625898","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484625898?lang=zh_cn&edition=full","pubTime":"2024-11-18 19:42","pubTimestamp":1731930130,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["NVO","01477","BK1191","IE00BKVL7J92.USD","LU0109394709.USD","IE00BZ1G4Q59.USD","LU0889565916.HKD","BK4568","LU0320765992.SGD","BK4588","LU1093756325.SGD","AZN","BK1574","LU0154236417.USD","BK4007","LU2456880835.USD","LU1829250122.USD","LU2236285917.USD","LU2462157665.USD","BK4585","LU1093756168.USD","BK4532","LU2417539215.USD"],"gpt_icon":0},{"id":"2484447796","title":"减重版司美格鲁肽在上海开出全国首批处方","url":"https://stock-news.laohu8.com/highlight/detail?id=2484447796","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484447796?lang=zh_cn&edition=full","pubTime":"2024-11-18 18:20","pubTimestamp":1731925237,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["GLP","IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756325.SGD","BK4532","BK4590","LU1093756168.USD","BK4588","IE00BKVL7J92.USD","BK4007","NVO","BK4144","BK4585"],"gpt_icon":0},{"id":"2484738696","title":"决定诺和诺德股价的关键：下一代减肥药数据下月公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2484738696","media":"华尔街见闻","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484738696?lang=zh_cn&edition=full","pubTime":"2024-11-18 12:44","pubTimestamp":1731905092,"startTime":"0","endTime":"0","summary":"诺和诺德将在下个月发布其“下一代”减肥药物CagriSema的最终临床实验数据，预计CagriSema能在一年多的时间内减少使用者25%的体重，有望占据GLP-1类减重药物的领先地位。","market":"us","thumbnail":"https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/3153c88188d79bb8182b93c4fdd43636"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3734340","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3734340","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"决定诺和诺德股价的关键：下一代减肥药数据下月公布","news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["BK4532","LU0154236417.USD","LU1093756325.SGD","NVO","BK4007","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4588","BK4585"],"gpt_icon":0},{"id":"2484523626","title":"周末要闻：马斯克或遭调查 诺和诺德减重药正式入华 字节跳动估值约3000亿美元 摩根大通获标普上调信用评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2484523626","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484523626?lang=zh_cn&edition=full","pubTime":"2024-11-18 06:21","pubTimestamp":1731882067,"startTime":"0","endTime":"0","summary":"欲览更多环球财经资讯，请移步7×24小时实时财经新闻。　　11月15日美股成交额前20：FTC将对微软云业务展开反垄断调查。　　欧洲主要股指集体收跌 德国DAX 30指数跌0.29%. 　　美联邦上诉法院同意暂停对特朗普机密文件案的上诉。　　TikTok母公司字节跳动对自身的估值约为3，000亿美元。　　摩根大通市场份额增长十年 获标普上调信用评级。　　马斯克或遭调查。　　诺和诺德GLP-1减重药正式入华，定价如何","market":"us","thumbnail":"https://n.sinaimg.cn/finance/transform/20151229/HltM-fxmykrf2567298.png","type":0,"news_type":0,"thumbnails":["https://n.sinaimg.cn/finance/transform/20151229/HltM-fxmykrf2567298.png"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":"062b6a3a1a6c8ab0097a6bd274c4fb0f","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/tob/2024-11-18/doc-incwmrax0633754.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["NVO"],"gpt_icon":1},{"id":"2484850686","title":"诺和诺德GLP-1减重药正式入华，定价如何","url":"https://stock-news.laohu8.com/highlight/detail?id=2484850686","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484850686?lang=zh_cn&edition=full","pubTime":"2024-11-17 17:52","pubTimestamp":1731837136,"startTime":"0","endTime":"0","summary":"11月17日，诺和诺德宣布其用于长期体重管理的胰高糖素样肽-1受体激动剂（GLP-1RA）周制剂司美格鲁肽（商品名：诺和盈）正式在中国上市，为中国超重和肥胖症患者提供减重选择。第一财经记者了解到，伴随着诺和盈的正式商业化，公立医院首张司美格鲁肽用于减重适应症的处方将于下周在上海开出。针对诺和盈的定价，诺和诺德方...","market":"us","thumbnail":"https://inews.gtimg.com/om_ls/OWIojXn_6BLSOc4MOSsEp3gQBaG32noJIXavvnMYKx720AA_294195/0","type":0,"news_type":0,"thumbnails":["https://inews.gtimg.com/om_ls/OWIojXn_6BLSOc4MOSsEp3gQBaG32noJIXavvnMYKx720AA_294195/0"],"rights":{"source":"tencent_tech","url":"https://new.qq.com/rain/a/20241117A05L0600","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.author, .pubtime{#sourceStyle#; display: inline-block;} .pubtime{margin-left: 3px;}strong{font-weight:500;#lv2TextColor#}","selectors":".main-wrapper","filters":".follow_top, .channel-entry, .collapseWrapper, .pic, .gap, .showDividingLine, .loader, .container, .ct-sumary, .nav, .landad, .hairline-top, .footer, .recommend-modules, .headroom-wrapper, .elevator","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://new.qq.com/rain/a/20241117A05L0600","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent_tech","symbols":["NVO","BK4585","BK4144","IE00BKVL7J92.USD","LU0154236417.USD","LU1093756168.USD","GLP","IE00BZ1G4Q59.USD","BK4532","BK4588","BK4007","BK4590","LU1093756325.SGD"],"gpt_icon":1},{"id":"2484884336","title":"诺和诺德减重用司美格鲁肽今日上市 将布局多渠道销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2484884336","media":"新京报","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484884336?lang=zh_cn&edition=full","pubTime":"2024-11-17 16:54","pubTimestamp":1731833689,"startTime":"0","endTime":"0","summary":"新京报贝壳财经讯（记者丁爽）11月17日，诺和诺德用于长期体重管理的司美格鲁肽注射液诺和盈正式在中国上市。针对诺和盈上市，在上市渠道方面，诺和诺德当日对新京报贝壳财经记者表示，公司将本着对患者负责的原则，增加药物的可及性，上市后根据肥胖症患者的分布，在包括公立医院、私立医院、药店渠道的多渠道布局该药品销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411173241771950.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411173241771950.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BZ1G4Q59.USD","LU1093756325.SGD","IE00BKVL7J92.USD","BK4532","NVO","BK4588","BK4585","LU0154236417.USD","BK4007","LU1093756168.USD"],"gpt_icon":1},{"id":"2484631501","title":"减重版司美格鲁肽中国上市：属处方药范畴，电商已有预约服务，单支超千元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484631501","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484631501?lang=zh_cn&edition=full","pubTime":"2024-11-17 14:45","pubTimestamp":1731825955,"startTime":"0","endTime":"0","summary":"马斯克亲测过的减重版司美格鲁肽终于在国内正式商业化上市。11月17日，诺和诺德中国在上海举办媒体发布会宣布，减重版司美格鲁肽正式在国内上市。该药是全球首个且目前唯一用于长期体重管理的胰高糖素样肽-1受体激动剂（GLP-1）周制剂，能够实现平均17%的体重降幅。司美格鲁肽是诺和诺德的王牌产品，也是全球GLP-1药物的代表。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411173241746650.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411173241746650.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BZ1G4Q59.USD","LU0154236417.USD","LU1093756325.SGD","BK4532","LU1093756168.USD","BK4588","IE00BKVL7J92.USD","BK4007","NVO","BK4585"],"gpt_icon":1},{"id":"2484050182","title":"诺和诺德：公司已经开始申请诺和盈的省级招标挂网","url":"https://stock-news.laohu8.com/highlight/detail?id=2484050182","media":"格隆汇","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484050182?lang=zh_cn&edition=full","pubTime":"2024-11-17 14:28","pubTimestamp":1731824888,"startTime":"0","endTime":"0","summary":"格隆汇11月17日｜据21财经，诺和诺德方面表示，公司已经开始申请诺和盈的省级招标挂网，具体定价可参考挂网价格。上市之后，诺和诺德将根据肥胖症患者在全国的分布进行涵盖公立医院、私立医院以及药店等全渠道的布局。北京大学人民医院内分泌科主任纪立农教授表示，肥胖症患者“互联网式”的减重方式可能造成对身体有害的减重与复胖的“体重震荡”，甚至因方法不当，导致更严重的健康问题。“因此，有临床减重需求的患者应前往正规医疗机构进行评估和诊断，开展科学的减重治疗。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117142814abc8d89c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117142814abc8d89c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU1093756325.SGD","BK4585","IE00BKVL7J92.USD","NVO","BK4007","LU1093756168.USD","IE00BZ1G4Q59.USD","BK4532","LU0154236417.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":0.0326},{"period":"1month","weight":-0.0923},{"period":"3month","weight":-0.233},{"period":"6month","weight":-0.2277},{"period":"1year","weight":0.0174},{"period":"ytd","weight":0.0156}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S于1989年成立，由两家丹麦公司，诺德根措夫特A/S和Novo工业A/S的合并而成。诺和诺德是一家全球性医疗保健公司，糖尿病治疗的全球领先者。公司拥有业界最广泛的糖尿病产品组合，其中包括新一代胰岛素，现代的完整产品组合，以及作为一个人每日一次的GLP-1类似物之一。此外，诺和诺德在血友病关怀，生长激素疗法和激素替代疗法中也处于领先地位。","yearOnYearQuotes":[{"month":1,"riseRate":0.534884,"avgChangeRate":0.122207},{"month":2,"riseRate":0.604651,"avgChangeRate":0.027007},{"month":3,"riseRate":0.465116,"avgChangeRate":0.01259},{"month":4,"riseRate":0.627907,"avgChangeRate":0.016402},{"month":5,"riseRate":0.545455,"avgChangeRate":0.017073},{"month":6,"riseRate":0.704545,"avgChangeRate":0.027554},{"month":7,"riseRate":0.5,"avgChangeRate":0.005498},{"month":8,"riseRate":0.522727,"avgChangeRate":0.001751},{"month":9,"riseRate":0.568182,"avgChangeRate":-0.002657},{"month":10,"riseRate":0.5,"avgChangeRate":-0.002241},{"month":11,"riseRate":0.613636,"avgChangeRate":0.026875},{"month":12,"riseRate":0.744186,"avgChangeRate":0.054828}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}